Clinical trials
Rectal Neoplasms trials in Italy with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 10 |
| Completed | 6 |
| Recruiting | 6 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 3 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2 |
| Fondazione del Piemonte per l'Oncologia | 2 |
| University of Rome Tor Vergata | 2 |
| ASL Verbano Cusio Ossola | 1 |
| Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria | 1 |
| Azienda Ospedaliera di Padova | 1 |
| Colospan Ltd. | 1 |
| Donato F Altomare | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Rectal Neoplasms | 24 |
| Anastomotic Leak | 7 |
| Colorectal Neoplasms | 4 |
| Colonic Neoplasms | 3 |
| Colonic Polyps | 1 |
| Postoperative Complications | 1 |
| Recurrence | 1 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.